Considering the successful application of lipid-nanoparticles (LNPs) as therapeutic agents in different cancer types [51], the prospects of delivering endogenous-ADAR to various cancers seem promising, as it requires the insertion of only a small payload containing a gRNA into the cell. The gene discussed is ADAR; the disease is cancer.